The Role of Para-Aortic Lymphadenectomy in the Surgical Staging of Women with Intermediate and High-Risk Endometrial Adenocarcinomas
Table 4
(a) Disease recurrence patterns in the PPALN and the PLN groups. (b) Overall survival analysis adjusting for recurrence site amongst patients who experienced a recurrence*.
(a)
PPALN
PLN
Chi-square value
Vagina
No
39 (84.8%)
24 (85.7%)
0.91
Yes
7 (15.2%)
4 (14.3%)
Pelvic lymph node
No
38 (82.6%)
24 (85.7%)
0.72
Yes
8 (17.4%)
4 (14.3%)
Pelvis
No
34 (73.9%)
22 (78.6%)
0.65
Yes
12 (26.1%)
6 (21.4%)
Para-aortic lymph node
No
33 (71.7%)
23 (82.1%)
0.31
Yes
13 (28.3%)
5 (17.9%)
Extraperitoneal
No
21 (45.7%)
12 (42.9%)
0.81
Yes
25 (54.3%)
16 (57.1%)
Abdomen
No
33 (71.7%)
13 (46.4%)
0.03
Yes
13 (28.3%)
15 (53.6%)
(b)
Alive
Dead
Age-adjusted HR (95% CI)
Fully adjusted* HR (95% CI)
Vagina
No
52 (82.5%)
11 (100.0%)
Yes
11 (17.5%)
0 (0%)
Pelvic lymph node
No
53 (84.1%)
9 (81.8%)
1.00
1.00
Yes
10 (15.9%)
2 (18.2%)
0.64 (0.12, 3.31)
0.22 (0.02, 2.43)
0.22
Pelvis
No
48 (76.2%)
8 (72.7%)
1.00
1.00
Yes
15 (23.8%)
3 (27.3%)
1.06 (0.28, 4.02)
1.41 (0.15, 13.1)
0.76
Para-aortic lymph node
No
48 (76.2%)
8 (72.7%)
1.00
1.00
Yes
15 (23.8%)
3 (27.3%)
0.46 (0.11, 1.93)
0.37 (0.04, 3.16)
0.36
Extraperitoneal
No
31 (49.2%)
2 (18.2%)
1.00
1.00
Yes
32 (50.8%)
9 (81.8%)
3.26 (0.69, 15.4)
10.9 (0.42, 285)
0.15
Abdomen
No
39 (61.9%)
7 (63.6%)
1.00
1.00
Yes
24 (38.1%)
4 (36.4%)
1.46 (0.39, 5.43)
1.19 (0.16, 8.87)
0.86
Adjusted for age (continuous), year of surgery (continuous), lymph nodes (PLN and PALN), histology (endometrioid/mixed, clear cell, and papillary serous), lymphovascular invasion, and myometrial invasion.
